102025-92-3

Upstream product

• 101597-79-9 4,5-dimethoxy-α-oxo-bibenzyl-2-carboxylic acid 
• 1376449-83-0 3-hydroxy-5,6-dimethoxy-2-phenyl-1H-inden-1-one 

Downstream Products

• 101440-97-5 1-chloro-4-benzyl-6,7-dimethoxyphthalazine 
• 39794-29-1 1-benzyl-6,7-dimethoxy-phthalazine 
• 1376449-84-1 1-(piperazin-1-yl)-4-benzyl-6,7-dimethoxyphthalazine 
• 1313223-33-4 C₃₀H₃₃N₅O₃ 
• 1313223-29-8 C₃₀H₃₀F₃N₅O₃ 
• 1313223-32-3 C₂₉H₃₀ClN₅O₃ 
• 1313223-31-2 C₃₀H₃₀F₃N₅O₄ 
• 1313223-36-7 C₂₉H₃₀FN₅O₃ 
• 1313223-45-8 C₃₁H₂₉F₆N₅O₃ 

Relevant academic research and scientific papers

Synthesis and cytotoxic evaluation of some new phthalazinylpiperazine derivatives

A new series of 1,4-disubstituted phthalazinylpiperazine derivatives 7a-f, 12a-f and 20a-f were designed and synthesized in order to develop potent and selective antitumor agents. The target compounds were screened for their cytotoxic activities against A549, HT-29 and MDA-MB-231 cancer cell lines in vitro. Among them, compounds 7a-f exhibited excellent selectivity for MDA-MB-231 with IC50 values ranging from 0.013 μM to 0.079 μM. The most promising compound, 7e (IC50 = 2.19 μM, 2.19 μM, 0.013 μM), was 9.3, 10, and 4.9 × 103 times more active than vatalanib (IC50 = 20.27 μM, 21.96 μM, 63.90 μM), respectively. A new series of 1,4-disubstituted phthalazinylpiperazine derivatives 7a-f, 12a-f and 20a-f were designed and synthesized, and their cytotoxic activities against A549, HT-29 and MDA-MB-231 cancer cell lines in vitro were compared to that of vatalanib.